 Argenx SE NASDAQ: ARGX has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous SC efgartigimod for generalized myasthenia gravis gMG. Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles. 